Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024 16:01 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024 08:10 ET
|
BioNTech SE
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron...
SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight
September 19, 2024 07:34 ET
|
KuicK Research
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...
The Wellness Genomics Market is expected to reach revenue of USD 108.9 Bn by 2033, at 14.8% CAGR: Dimension Market Research.
September 18, 2024 12:17 ET
|
Dimension Market Research
New York, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Wellness Genomics Market is projected to reach USD 31.5 billion in 2024 and is expected to grow to USD 108.9 billion by...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
September 18, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
September 17, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory...
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024 06:45 ET
|
BioNTech SE
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day,...
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
September 16, 2024 08:00 ET
|
BioAtla, Inc.
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin’s activity in a high unmet need SCCHN patient...
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
September 16, 2024 07:00 ET
|
PDS Biotechnology Corporation
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024 08:45 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion...